CLOV at a glance
CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV, SEC CIK 1801170) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on September 25, 2026 and Form 4 insider filings as recently as October 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) reported revenue of $1.9 billion (up 40.3% from FY2024) and a net loss of $85.5 million.
- As of June 30, 2026, 30 institutional investment managers tracked by SignalX reported holding CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) shares worth $497.9 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Reynoso Jamie L. on October 5, 2026 of 8,750 shares at $4.42 per share.
- In the last 90 days, CLOV insiders reported 0 open-market purchases ($0) and 17 open-market sales ($4.3M) on Form 4, a net sale of $4.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.9B
- +40.3% vs prior year
- Insiders · 90 days
- 0 buys · 17 sells
- Net −$4.3M
- 13F holders
- 30 funds
- $497.9M · +1 vs prior quarter
- Latest 8-K
- Sep 25, 2026
- Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $743.2M, up 55.6% YoY from $477.6M, driven by 49% membership growth
- Net income $28.0M vs $10.6M loss YoY; operating margin 3.8% vs negative 2.2%
- PPO plans’ premiums earned $737.8M, up 57%; Insurance benefits ratio 87.6% vs 88.4% YoY
- Adjusted SG&A margin 15.1% vs 17.3%; quarterly Adjusted EBITDA $40.9M vs $17.1M
- Cash, cash equivalents, and investments $443.0M at June 30; 2027 payment outlook supported by 4.5-Star PPO and HMO ratings
Risk Factors
- No material changes disclosed from Item 1A of the 2025 Form 10-K
- Carried-forward risk disclosures may adversely affect business, financial condition, and results of operations
- Multiple risk factors could materially reduce Class A common stock market price
AI summary of the CLOV 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Two directors appointed effective immediately, filling vacancies and expanding the Board to nine directors
- Former Senator Torricelli joins the Audit Committee, adding federal healthcare policy and business oversight experience
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Senator Torricelli and Dr. Miller appointed as directors, expanding board oversight and healthcare-policy expertise
- Dr. Miller brings Medicare, regulatory, clinical medicine and health-plan governance experience
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Senator Torricelli and Dr. Miller appointed as directors, expanding board oversight
- Dr. Miller adds clinical, Medicare policy, regulatory and health-plan governance expertise
Item EX-99.1: Item EX-99.1
- Former Senator Robert Torricelli and Dr. Brian J. Miller appointed directors, filling two vacancies
- Board expanded to nine directors, strengthening governance capacity
Item 7.01: Regulation FD Disclosure
- Clover Health published written responses to selected shareholder questions following its Q2 2026 earnings announcement
- Supplemental responses furnished as Exhibit 99.1 and posted on the investor relations website
Item EX-99.1: Item EX-99.1
- CA-managed year-3 members generate approximately $155 PMPM more insurance gross profit than year-1 members
- CA-managed members show approximately 18% better MCR in year 3, supporting Clover’s cohort-maturation earnings thesis
AI summaries of CLOV 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CLOV
Don't miss the next CLOV filing
- Alerts as it files. A push when CLOV files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CLOV, by share count.
- Ask anything. An AI agent that reads every CLOV filing and answers with sources.
CLOV alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Reynoso Jamie L. | Sell | Oct 5, 2026 | 8,750 | $4.42 |
| Toy Andrew | Sell | Oct 1, 2026 | 318,806 | $4.19 |
| Torricelli Robert G | A | Sep 30, 2026 | 12,481 | - |
| Miller Brian James | A | Sep 30, 2026 | 12,481 | - |
| Reynoso Jamie L. | Sell | Sep 17, 2026 | 1,921 | $4.56 |
| OLDAKOWSKI JOSEPH FRANK | Sell | Sep 16, 2026 | 3,170 | $4.64 |
| Reynoso Jamie L. | Sell | Sep 15, 2026 | 9,273 | $4.78 |
| Soares Karen | Sell | Sep 15, 2026 | 6,846 | $4.78 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.4B | $1.9B |
| Operating Income | - | -$45.7M | -$85.5M |
| Net Income | -$213.4M | -$43.0M | -$85.5M |
| Op. Margin | - | -3.3% | -4.4% |
| Net Margin | - | -3.1% | -4.4% |
| Balance Sheet | |||
| Total Assets | $570.7M | $580.7M | $541.0M |
| Equity | $286.4M | $341.1M | $308.7M |
| ROE | -74.5% | -12.6% | -27.7% |
| Per Share | |||
| EPS | $-0.44 | - | - |
| Cash Flow | |||
| Operating CF | -$115.9M | $34.8M | -$66.9M |
| CapEx | $584K | $1.6M | $2.0M |
Source: XBRL data in CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CLOV share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 30 | $497.9M |
| Q1 2026 | 29 | $153.8M |
| Q4 2025 | 26 | $218.0M |
| Q3 2025 | 29 | $282.7M |
| Q2 2025 | 28 | $283.9M |
| Q1 2025 | 20 | $205.4M |
| Q4 2024 | 16 | $142.9M |
| Q3 2024 | 14 | $74.7M |
- BlackRock+3.27M (+10%)
- D.E. Shaw & Co+1.87M (+2060%)
- Vanguard Capital Management LLC+1.06M (+6%)
- Vanguard Portfolio Management LLC+774.0K (+21%)
- State Street Corp+620.4K (+6%)
- Goldman Sachs Group−994.8K (-46%)
- Renaissance Technologies LLC−594.1K (-17%)
- Dimensional Fund Advisors−269.2K (-8%)
- PNC Financial Services−200.2K (-5%)
- Millennium Management−56.2K (-5%)
- Blackstone Group+64.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 192 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CLOV filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 8-K | Sep 25, 2026 | - | Analysis | - |
| 8-K | Sep 24, 2026 | - | Analysis | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 8-K | Aug 20, 2026 | - | Analysis | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 10-Q | Aug 7, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jul 20, 2026 | - | - | - |
| 8-K | Jul 17, 2026 | - | Analysis | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 16, 2026 | - | - | - |
| 4 | Jul 16, 2026 | - | - | - |
| 4 | Jul 16, 2026 | - | - | - |
Related Health Care companies
- ALHC · Alignment Healthcare, Inc.Hospital & Medical Service Plans
- CNC · Centene CorporationHospital & Medical Service Plans
- CI · CignaHospital & Medical Service Plans
- ELV · Elevance HealthHospital & Medical Service Plans
- HUM · HumanaHospital & Medical Service Plans
- MOH · Molina HealthcareHospital & Medical Service Plans
- OSCR · Oscar Health, Inc.Hospital & Medical Service Plans
- TRUP · TRUPANION, INC.Hospital & Medical Service Plans
CLOV SEC filings: frequently asked questions
Are CLOV insiders buying or selling?
In the last 90 days, CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) officers, directors and 10% owners reported no open-market purchases and 17 open-market sales worth $4.3 million by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CLOV stock?
As of June 30, 2026, the largest CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) holders among the 13F filers tracked by SignalX were BlackRock ($184.0 million), Vanguard Capital Management LLC ($94.5 million), State Street Corp ($53.3 million), Vanguard Portfolio Management LLC ($23.4 million), Northern Trust ($19.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CLOV's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) reported revenue of $1.9 billion (up 40.3% from FY2024) and a net loss of $85.5 million. The figures come from the XBRL data in the 10-K.
What did CLOV report in its latest 8-K?
CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an 8-K on September 25, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Two directors appointed effective immediately, filling vacancies and expanding the Board to nine directors.
What are the latest CLOV SEC filings?
CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on September 25, 2026 and a Form 4 insider filing on October 5, 2026.
What is CLOV's SEC CIK number?
CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)'s SEC Central Index Key (CIK) is 1801170. EDGAR lists every CLOV filing under that number.
Ask anything about CLOV
The research agent reads CLOV's filings, financials, insider trades and 13F holders, then answers with sources.